Novartis Chief Executive Says FDA Succumbing to Political Pressure in its Attempt to Increase Drug Safety

Joe Saunders

Attorney
(866) 735-1102 Ext 340

0 CommentsPrint ArticleSubscribe

During the three day Clinton Global Initiative, Novartis Chief Executive Dan Vasella said that the FDA was buckling under political pressure to monitor the safety and efficacy of new pharmaceuticals. HIs comments were made in the wake of rising awareness of overly aggressive marketing tacticts by pharmaceutical companies at the expense of consumer safety. Two Novartis drugs, Prexige and Galvus have met significant regulatory delays in the US in spite of being approved in other parts of the world. Vasella didn't comment on the number of drugs including Merck, Zyprexa, and Avandia, to name a few. Big pharma has been playing money politics with consumer safety for years now. It's about time the FDA increased its monitoring of drug safety.

For more information on this subject, please refer to our section on Drugs, Medical Devices, and Implants.